The global liquid biopsy market is witnessing robust expansion, driven by rising cancer prevalence and growing demand for non-invasive diagnostics. Valued at US$3.65 billion in 2024, the market is projected to reach US$4.03 billion in 2025 and is anticipated to grow at a CAGR of 11.8% from 2025 to 2030, achieving US$7.05 billion by 2030. The increasing emphasis on early detection and precision medicine, coupled with the ability of liquid biopsies to provide real-time insights into tumor dynamics, underpins this growth. These tests are also gaining popularity in non-invasive prenatal testing and organ transplantation monitoring, further widening their clinical applications.

Advancements in next-generation sequencing (NGS), biomarker identification, and molecular diagnostics have significantly improved the sensitivity and accuracy of liquid biopsy tests. Rising public and private investments in precision oncology and the growing need for early, non-invasive disease detection are further accelerating adoption.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350

Key Market Opportunities and Regional Insights

The Asia Pacific region presents substantial opportunities due to rising cancer incidence, improved healthcare infrastructure, increased investment in diagnostic innovation, and growing awareness of early cancer screening. Meanwhile, North America held the largest share of the global liquid biopsy market in 2024, supported by advanced R&D capabilities, a well-established healthcare system, and strong adoption of precision oncology technologies.

Collaborations, partnerships, and product launches remain the key growth strategies among major players in the market.

Global Market Dynamics

Driver – Rising Cancer Incidence:
The surging global cancer burden remains the primary driver for market expansion. As cancer cases increase, the need for diagnostic tools capable of early detection, treatment monitoring, and resistance tracking becomes crucial. Liquid biopsy offers a non-invasive and repeatable method for detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers. Its ability to support personalized treatment decisions and ongoing monitoring enhances its value in oncology care.

Restraint – Limited Sensitivity and Specificity:
Despite rapid innovation, some liquid biopsy tests still face challenges related to low sensitivity and specificity, particularly in detecting ctDNA at very low concentrations. This can lead to false-negative results, reducing diagnostic reliability and clinical confidence.

Opportunity – Expanding Role of Companion Diagnostics:
The growing focus on companion diagnostics offers significant growth potential. As precision medicine advances, liquid biopsy serves as a valuable tool for identifying patients most likely to benefit from targeted therapies. Collaborations between diagnostic developers and pharmaceutical companies are increasing, promoting the integration of liquid biopsy in personalized cancer treatment.

Challenge – Unfavorable Reimbursement Landscape:
Inconsistent reimbursement policies remain a key barrier to widespread adoption. High testing costs, limited insurance coverage, and a lack of pricing transparency hinder accessibility. Although some payers now cover multi-gene panels, restrictions often limit the full potential of liquid biopsy applications.

Market Ecosystem Overview

The liquid biopsy ecosystem includes reference laboratories, hospitals, physician labs, and academic research centers. Based on circulating biomarkers, the market is divided into CTCs, ctDNA, cell-free DNA (cfDNA), and extracellular vesicles. Among these, the ctDNA segment is expected to grow at the highest CAGR due to its superior sensitivity, real-time monitoring capabilities, and growing use in precision oncology and drug resistance detection.

By sample type, blood-based liquid biopsies dominate the market owing to their cost-effectiveness, convenience, and strong clinical validation across multiple cancer types.

Regional Analysis

In 2024, North America led the market due to the presence of major diagnostic players, ongoing technological innovation, and strong healthcare infrastructure. The United States remains the largest market within the region, driven by rapid adoption of advanced cancer diagnostics.

Recent Developments

• April 2025: Natera, Inc. launched its ultra-sensitive Signatera Genome-MRD test in the U.S.
• February 2025: Myriad Genetics partnered with Gabbi to integrate hereditary cancer testing and telehealth solutions for breast cancer risk assessment.
• February 2024: Myriad Genetics acquired select assets from Intermountain Health’s precision genomics lab business.
• January 2024: Natera acquired non-invasive prenatal testing assets from Invitae (U.S.).

Key Market Players

Leading companies in the global liquid biopsy market include:
Natera, Inc. (U.S.), QIAGEN (Netherlands), Myriad Genetics, Inc. (U.S.), Illumina, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Guardant Health (U.S.), Bio-Rad Laboratories (U.S.), Exact Sciences Corporation (U.S.), Sysmex Corporation (Japan), GRAIL, Inc. (U.S.), and Menarini-Silicon Biosystems (Italy).

These companies are actively advancing innovations in ctDNA detection, multi-cancer early detection, and companion diagnostic integration, reinforcing liquid biopsy’s position as a cornerstone of future precision medicine.